Which monoclonal antibody carries the major risk for MRONJ (medication-related osteonecrosis of the jaw)?

Denosumab is a monoclonal antibody that directly inhibits RANKL, powerfully suppressing osteoclast activity (similar antiresorptive effect to bisphosphonates) — making it the antibody most strongly and specifically linked to MRONJ. Bevacizumab (an antiangiogenic antibody) carries a real but comparatively lower MRONJ risk, and adalimumab (an anti-TNF immunosuppressant used for autoimmune disease) is not significantly associated with MRONJ.